Detail akcie Mainz Biomed Rg online

Business Summary: Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Mainz Biomed NV revenues decreased 45% to $287K. Net loss decreased 24% to $8.3M. Revenues reflect Revenue decrease of 61% to $204K. Lower net loss reflects Genetic diagnostic testing segment loss decrease of 17% to $8.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$19.73 to -$2.65.